Surgical neurology international · 2025
BurstDR™ spinal cord stimulation for chemotherapy-induced peripheral neuropathy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jaffee Stephen, Mamagdi Jyothika, Vaezi Miriam, Kite Trent, Gupta Bhavika, Valleta Samuel, Monaco Feno, Tomycz Nestor
Аннотация
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common persistent adverse effects of chemotherapy affecting cancer survivors. Other than the use of duloxetine, no other intervention has a proven benefit for these patients. Here, a patient with multiple myeloma who developed CIPN experienced a significant reduction in their symptoms after the implantation of a spinal cord stimulator.
CASE DESCRIPTION: A 64-year-old male with a history of multiple myeloma presented with chronic pain 4 years after chemotherapy, followed by an autologous stem cell transplant. As the patient's symptoms were refractory to medical management, he underwent placement of a permanent spinal cord stimulator, resulting in 80% relief of calf pain and a 60% improvement in foot paresthesias/pain.
CONCLUSION: Spinal cord stimulation proved effective in treating CIPN (CIPN following autologous stem cell transplant) in a 64-year-old male treated 4 years ago for multiple myeloma.
CASE DESCRIPTION: A 64-year-old male with a history of multiple myeloma presented with chronic pain 4 years after chemotherapy, followed by an autologous stem cell transplant. As the patient's symptoms were refractory to medical management, he underwent placement of a permanent spinal cord stimulator, resulting in 80% relief of calf pain and a 60% improvement in foot paresthesias/pain.
CONCLUSION: Spinal cord stimulation proved effective in treating CIPN (CIPN following autologous stem cell transplant) in a 64-year-old male treated 4 years ago for multiple myeloma.